Topical verapamil and episcleral venous pressure

Marcio Marc Abreu, Yong Yeon Kim, Dong H. Shin, Peter A. Netland

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To investigate the effect of a single-dose and 2-week administration of topical 0.25% verapamil on episcleral venous pressure (EVP) and intraocular pressure (IOP). Design: A prospective, randomized, double- masked, crossover, and placebo-controlled study. Participants: One eye of each of 20 normal subjects received topical verapamil or placebo. Intervention: The EVP was measured using a pressure chamber episcleral renomanometer. The IOP, EVP, heart rate (HR), and blood pressure (BP) were measured at baseline, 1.5 hours after a single drop, and after 2-week, three- times-a-day topical administration of 0.25% verapamil or placebo to one eye. After a 4-week washout period, the treatment to the study eye was reversed, and measurements of EVP, IOP, HR, and BP were repeated. Main Outcome Measures: The EVP, IOP, HR, and BP were measured. Results: Ninety minutes after a single drop, the EVP in the verapamil-treated eyes was reduced by 4.8% (P = <0.001) and in the untreated fellow eyes by 2.4% (P = 0.032). After 2-week topical administration, the EVP was reduced by 9.5% (P = <0.0001) in the verapamil-treated eyes and by 4.8% (P = 0.001) in the fellow eyes. The EVP was unchanged in the treated and fellow eyes after a single drop or after a 2-week treatment with placebo. Ninety minutes after topical administration of 0.25% verapamil, the IOP decreased by 7.7% (P = <0.0001) in the treated eyes and decreased by 3.6% (P = 0.03) in the fellow eyes. After a 2-week administration of topical verapamil, the IOP decreased by 12% (P = 0.0001) in the treated eyes and by 7.2% (P = 0.0289) in the fellow eyes. The changes of IOP in the placebo-treated and fellow eyes were not statistically significant after a single-dose and 2-week administration. After topical administration of verapamil, a contralateral effect on IOP and EVP was observed in the fellow, untreated eye. No systemic effect on HR or BP was detected after a single-dose administration of topical verapamil. There were, however, significant reductions in HR and BP after a 2-week treatment with topical 0.25% verapamil. Conclusion: These results indicate that a single drop and a 2-week administration of topical 0.25% verapamil decrease IOP and EVP significantly, with more pronounced reduction after a 2-week treatment than after a single-dose treatment.

Original languageEnglish
Pages (from-to)2251-2255
Number of pages5
JournalOphthalmology
Volume105
Issue number12
Publication statusPublished - 1998 Dec 1
Externally publishedYes

Fingerprint

Venous Pressure
Verapamil
Topical Administration
Intraocular Pressure
Heart Rate
Placebos
Blood Pressure
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Abreu, M. M., Kim, Y. Y., Shin, D. H., & Netland, P. A. (1998). Topical verapamil and episcleral venous pressure. Ophthalmology, 105(12), 2251-2255.

Topical verapamil and episcleral venous pressure. / Abreu, Marcio Marc; Kim, Yong Yeon; Shin, Dong H.; Netland, Peter A.

In: Ophthalmology, Vol. 105, No. 12, 01.12.1998, p. 2251-2255.

Research output: Contribution to journalArticle

Abreu, MM, Kim, YY, Shin, DH & Netland, PA 1998, 'Topical verapamil and episcleral venous pressure', Ophthalmology, vol. 105, no. 12, pp. 2251-2255.
Abreu MM, Kim YY, Shin DH, Netland PA. Topical verapamil and episcleral venous pressure. Ophthalmology. 1998 Dec 1;105(12):2251-2255.
Abreu, Marcio Marc ; Kim, Yong Yeon ; Shin, Dong H. ; Netland, Peter A. / Topical verapamil and episcleral venous pressure. In: Ophthalmology. 1998 ; Vol. 105, No. 12. pp. 2251-2255.
@article{b4bf66a02d28497fa2ad9f15ee964ba7,
title = "Topical verapamil and episcleral venous pressure",
abstract = "Objective: To investigate the effect of a single-dose and 2-week administration of topical 0.25{\%} verapamil on episcleral venous pressure (EVP) and intraocular pressure (IOP). Design: A prospective, randomized, double- masked, crossover, and placebo-controlled study. Participants: One eye of each of 20 normal subjects received topical verapamil or placebo. Intervention: The EVP was measured using a pressure chamber episcleral renomanometer. The IOP, EVP, heart rate (HR), and blood pressure (BP) were measured at baseline, 1.5 hours after a single drop, and after 2-week, three- times-a-day topical administration of 0.25{\%} verapamil or placebo to one eye. After a 4-week washout period, the treatment to the study eye was reversed, and measurements of EVP, IOP, HR, and BP were repeated. Main Outcome Measures: The EVP, IOP, HR, and BP were measured. Results: Ninety minutes after a single drop, the EVP in the verapamil-treated eyes was reduced by 4.8{\%} (P = <0.001) and in the untreated fellow eyes by 2.4{\%} (P = 0.032). After 2-week topical administration, the EVP was reduced by 9.5{\%} (P = <0.0001) in the verapamil-treated eyes and by 4.8{\%} (P = 0.001) in the fellow eyes. The EVP was unchanged in the treated and fellow eyes after a single drop or after a 2-week treatment with placebo. Ninety minutes after topical administration of 0.25{\%} verapamil, the IOP decreased by 7.7{\%} (P = <0.0001) in the treated eyes and decreased by 3.6{\%} (P = 0.03) in the fellow eyes. After a 2-week administration of topical verapamil, the IOP decreased by 12{\%} (P = 0.0001) in the treated eyes and by 7.2{\%} (P = 0.0289) in the fellow eyes. The changes of IOP in the placebo-treated and fellow eyes were not statistically significant after a single-dose and 2-week administration. After topical administration of verapamil, a contralateral effect on IOP and EVP was observed in the fellow, untreated eye. No systemic effect on HR or BP was detected after a single-dose administration of topical verapamil. There were, however, significant reductions in HR and BP after a 2-week treatment with topical 0.25{\%} verapamil. Conclusion: These results indicate that a single drop and a 2-week administration of topical 0.25{\%} verapamil decrease IOP and EVP significantly, with more pronounced reduction after a 2-week treatment than after a single-dose treatment.",
author = "Abreu, {Marcio Marc} and Kim, {Yong Yeon} and Shin, {Dong H.} and Netland, {Peter A.}",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "105",
pages = "2251--2255",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Topical verapamil and episcleral venous pressure

AU - Abreu, Marcio Marc

AU - Kim, Yong Yeon

AU - Shin, Dong H.

AU - Netland, Peter A.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Objective: To investigate the effect of a single-dose and 2-week administration of topical 0.25% verapamil on episcleral venous pressure (EVP) and intraocular pressure (IOP). Design: A prospective, randomized, double- masked, crossover, and placebo-controlled study. Participants: One eye of each of 20 normal subjects received topical verapamil or placebo. Intervention: The EVP was measured using a pressure chamber episcleral renomanometer. The IOP, EVP, heart rate (HR), and blood pressure (BP) were measured at baseline, 1.5 hours after a single drop, and after 2-week, three- times-a-day topical administration of 0.25% verapamil or placebo to one eye. After a 4-week washout period, the treatment to the study eye was reversed, and measurements of EVP, IOP, HR, and BP were repeated. Main Outcome Measures: The EVP, IOP, HR, and BP were measured. Results: Ninety minutes after a single drop, the EVP in the verapamil-treated eyes was reduced by 4.8% (P = <0.001) and in the untreated fellow eyes by 2.4% (P = 0.032). After 2-week topical administration, the EVP was reduced by 9.5% (P = <0.0001) in the verapamil-treated eyes and by 4.8% (P = 0.001) in the fellow eyes. The EVP was unchanged in the treated and fellow eyes after a single drop or after a 2-week treatment with placebo. Ninety minutes after topical administration of 0.25% verapamil, the IOP decreased by 7.7% (P = <0.0001) in the treated eyes and decreased by 3.6% (P = 0.03) in the fellow eyes. After a 2-week administration of topical verapamil, the IOP decreased by 12% (P = 0.0001) in the treated eyes and by 7.2% (P = 0.0289) in the fellow eyes. The changes of IOP in the placebo-treated and fellow eyes were not statistically significant after a single-dose and 2-week administration. After topical administration of verapamil, a contralateral effect on IOP and EVP was observed in the fellow, untreated eye. No systemic effect on HR or BP was detected after a single-dose administration of topical verapamil. There were, however, significant reductions in HR and BP after a 2-week treatment with topical 0.25% verapamil. Conclusion: These results indicate that a single drop and a 2-week administration of topical 0.25% verapamil decrease IOP and EVP significantly, with more pronounced reduction after a 2-week treatment than after a single-dose treatment.

AB - Objective: To investigate the effect of a single-dose and 2-week administration of topical 0.25% verapamil on episcleral venous pressure (EVP) and intraocular pressure (IOP). Design: A prospective, randomized, double- masked, crossover, and placebo-controlled study. Participants: One eye of each of 20 normal subjects received topical verapamil or placebo. Intervention: The EVP was measured using a pressure chamber episcleral renomanometer. The IOP, EVP, heart rate (HR), and blood pressure (BP) were measured at baseline, 1.5 hours after a single drop, and after 2-week, three- times-a-day topical administration of 0.25% verapamil or placebo to one eye. After a 4-week washout period, the treatment to the study eye was reversed, and measurements of EVP, IOP, HR, and BP were repeated. Main Outcome Measures: The EVP, IOP, HR, and BP were measured. Results: Ninety minutes after a single drop, the EVP in the verapamil-treated eyes was reduced by 4.8% (P = <0.001) and in the untreated fellow eyes by 2.4% (P = 0.032). After 2-week topical administration, the EVP was reduced by 9.5% (P = <0.0001) in the verapamil-treated eyes and by 4.8% (P = 0.001) in the fellow eyes. The EVP was unchanged in the treated and fellow eyes after a single drop or after a 2-week treatment with placebo. Ninety minutes after topical administration of 0.25% verapamil, the IOP decreased by 7.7% (P = <0.0001) in the treated eyes and decreased by 3.6% (P = 0.03) in the fellow eyes. After a 2-week administration of topical verapamil, the IOP decreased by 12% (P = 0.0001) in the treated eyes and by 7.2% (P = 0.0289) in the fellow eyes. The changes of IOP in the placebo-treated and fellow eyes were not statistically significant after a single-dose and 2-week administration. After topical administration of verapamil, a contralateral effect on IOP and EVP was observed in the fellow, untreated eye. No systemic effect on HR or BP was detected after a single-dose administration of topical verapamil. There were, however, significant reductions in HR and BP after a 2-week treatment with topical 0.25% verapamil. Conclusion: These results indicate that a single drop and a 2-week administration of topical 0.25% verapamil decrease IOP and EVP significantly, with more pronounced reduction after a 2-week treatment than after a single-dose treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032471168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032471168&partnerID=8YFLogxK

M3 - Article

VL - 105

SP - 2251

EP - 2255

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 12

ER -